| Dr Benjamin Jacob Colburn, MD | |
|
10100 Se Sunnyside Rd, Clackamas, OR 97015-8970 | |
| (503) 494-8211 | |
| Not Available |
| Full Name | Dr Benjamin Jacob Colburn |
|---|---|
| Gender | Male |
| Speciality | Student In An Organized Health Care Education/training Program |
| Location | 10100 Se Sunnyside Rd, Clackamas, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104357714 | NPI | - | NPPES |
| Entity Name | Kaiser Foundation Health Plan Of The Northwest |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184786527 PECOS PAC ID: 5799688230 Enrollment ID: O20040220000099 |
News Archive
An education programme which successfully cut the level of obesity in children by teaching them about healthy eating and discouraging fizzy drinks was no longer effective three years after the intervention came to an end, according to a study published on bmj.com today.
When researchers at the Chang Gung University Medical College, Taiwan and the University of Pittsburgh School of Medicine injected botulinum toxin A, or Botox, into the prostate gland of men with benign prostatic hyperplasia (BPH), a condition commonly referred to as enlarged prostate, they found that it eased symptoms and improved quality of life.
Interferon - a critical protein that mediates the body's defense against a wide variety of infectious agents and tumors - may soon have greater therapeutic value as the result of a new study by researchers at Washington University School of Medicine in St. Louis.
Scientists of Helmholtz Zentrum München and the Munich University Hospital are developing a novel antibody to treat brain tumors.
Amgen Inc. today announced that the European Commission (EC) has granted marketing authorization for Prolia® (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Benjamin Jacob Colburn, MD 500 Ne Multnomah St Ste 100, Portland, OR 97232-2031 Ph: (503) 494-8211 | Dr Benjamin Jacob Colburn, MD 10100 Se Sunnyside Rd, Clackamas, OR 97015-8970 Ph: (503) 494-8211 |
News Archive
An education programme which successfully cut the level of obesity in children by teaching them about healthy eating and discouraging fizzy drinks was no longer effective three years after the intervention came to an end, according to a study published on bmj.com today.
When researchers at the Chang Gung University Medical College, Taiwan and the University of Pittsburgh School of Medicine injected botulinum toxin A, or Botox, into the prostate gland of men with benign prostatic hyperplasia (BPH), a condition commonly referred to as enlarged prostate, they found that it eased symptoms and improved quality of life.
Interferon - a critical protein that mediates the body's defense against a wide variety of infectious agents and tumors - may soon have greater therapeutic value as the result of a new study by researchers at Washington University School of Medicine in St. Louis.
Scientists of Helmholtz Zentrum München and the Munich University Hospital are developing a novel antibody to treat brain tumors.
Amgen Inc. today announced that the European Commission (EC) has granted marketing authorization for Prolia® (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
› Verified 3 days ago